Pancreas regeneration: pancreatic progenitors and their niche
POSTDOCTORAL RESEARCHERS
Joan Casamitjana i Vicente
PREDOCTORAL RESEARCHERS
Ángel Fernández Ruiz
Adrian Holguin Horcajo
Regenerative Medicine
Regenerative Medicine
Scientific production
2
PAPERS
Average IF: 16,1
2 PUBLICATION IN FIRST DECILE
2 PUBLICATIONS IN FIRST QUARTILE
2 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Villarroya Beltri,C;Martins,A;García,A;Giménez,D;Zarzuela,E;Novo,M;Del Álamo,C et al, Mammalian CDC14 phosphatases control exit from stemness in pluripotent cells., Embo J., 2023;42(1):doi:10.15252/embj.2022111251
- Kovatcheva,M;Melendez,E;Chondronasiou,D;Pietrocola,F;Bernad,R;Caballe,A;Junza,A et al, Vitamin B12 is a limiting factor for induced cellular plasticity and tissue repair, Nat. Metab., 2023;5(11):1911-1930, doi:10.1038/s42255-023-00916-6
Research highlights
PROJECTS
2 granted competitive projects
3 ongoing competitive projects
1 ongoing non competitive project
NETWORKS
ASEICA
EASD
CIBER-BBN
SCB
Selected projects
- PSJ23052. THE CELL OF ORIGIN OF PANCREATIC CANCER: NOVEL OPPORTUNITIES FOR THE EARLY DIAGNOSIS AND TREATMENT. FUNDACIÓN CRIS DE INVESTIGACIÓN PARA VENCER EL CÁNCER CRIS CONTRA EL CÁNCER. Budget: 1.231.423,1€. 2023- . PI: Rovira Clusellas, Meritxell.
- LCX22021. The cell of origin of Pancreatic Cancer: novel opportunities for the early diagnosis and treatment (oriPDAC4diagTreat). FUNDACIÓ “LA CAIXA”. Budget: 323.980€. 2023-2026. PI: Rovira Clusellas, Meritxell.
- INT21020. Comprehensive characterization of human ductal epithelium to identify endogenous progenitors as beta cell source.. EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES (EFSD). Budget: 50.448€. 2022-2024. PI: Rovira Clusellas, Meritxell; Montanya Mias, Eduard.
- 19PNJ139. Células ductales pancreáticas como fuente de células beta para el tratamiento de diabetes. l’oreal-UNESCO. 2019- . PI: Rovira Clusellas, Meritxell.
- DON23031. Organoids for diabetes treatment. Bon Preu. Budget: 25.907€. 2024-2025. PI: Rovira Clusellas, Meritxell.